OncoVee™-MiniPDX-guided anticancer treatment for HER2-negative intermediate-advanced gastric cancer patients: a single-arm, open-label phase I clinical study

BACKGROUND: Chemotherapy is the main treatment strategy for patients with advanced HER2-negative gastric cancer (GC); yet, many patients do not respond well to treatment. This study evaluated the sensitivity of a mini patient-derived xenograft (MiniPDX) animal model in patients with HER2-negative in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Baonan, Li, Yuzhen, Zhu, Xiaodan, Chen, Zhe, Huang, Xiaona, Gong, Tingjie, Zheng, Weiwang, Bi, Zhenle, Zhu, Chenyang, Qian, Jingyi, Li, Xiaoqiang, Jin, Chunhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126180/
https://www.ncbi.nlm.nih.gov/pubmed/37093368
http://dx.doi.org/10.1007/s12672-023-00661-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126180/
https://www.ncbi.nlm.nih.gov/pubmed/37093368
http://dx.doi.org/10.1007/s12672-023-00661-y

Ejemplares similares